title: [Current aspects of diagnosis and treatment of atopic diseases complicated by secondary immunodeficiency].
abstract: OBJECTIVE
  The study of clinicoimmunological features of current course of atopic diseases (AD) and design of effective etiopathogenic scheme of treating AD complicated by secondary immunodeficiency (SID).
  
  
  METHODS
  After comprehensive clinical, instrumental, x-ray, functional and bacteriological investigations 186 AD patients were divided into 4 groups: 25 patients untreated by immunomodulators (controls), 35 patients treated by diuciphone (200 g i.m. each other day for 12 days), 83 patients treated by polyoxidonium (6 mg i.m. each other day for 12 days, a total course dose 30 mg, or 6 mg i.m. daily for 2 days then 6 mg each other day for 3 days then 6 mg twice a week for 14 days, a course dose 45 mg), 33 patients received likopid (1 or 10 mg daily per os for 10 days or 10 mg daily for 10 days then 2 mg twice a week for 14 days).
  
  
  RESULTS
  A scheme of combined 3-staged treatment of AD complicated by SID is suggested. Stage 1-conventional treatment inhibiting aggravation of atopic reaction, improving functional condition of the defense systems plus antiinfection therapy, immunomodulators. Stage 2-primarily specific immunotherapy. Stage 3-outpatient prophylaxis of immunodeficiency and resistant forms of atopic reactions.
  
  
  CONCLUSIONS
  Combined staged pharmacological and immunological control of allergic inflammation and immunodeficiency is the main principle of control of AD with SID.
authors.forename: G N
authors.initials: GN
authors.lastname: Mikheeva
authors.forename: R M
authors.initials: RM
authors.lastname: Khaitov
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D007073:Immunoglobulin E / Q000276:immunology; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology; D012189:Retrospective Studies; D013450:Sulfones / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000888:Antibodies, Anti-Idiotypic; D004338:Drug Combinations; D013450:Sulfones; C089161:glikopin; C023367:diucifon; D007073:Immunoglobulin E; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D014498:Uracil
vernacular_title: Sovremennye aspekty diagnostiki i lecheniia atopicheskikh zabolevaniĭ, oslozhnennykh vtorichnoĭ immunnoĭ nedostatochnost'iu.